Results 161 to 170 of about 12,469 (206)

Progressive Multifocal Leukoencephalopathy

Seminars in Neurology, 1999
Before the AIDS epidemic, progressive multifocal leukoencephalopathy (PML) was a rare disorder occurring most often in association with leukemia and lymphoma. Current estimates indicate that PML ultimately develops in up to 5% of all patients with AIDS.
Eugene O Major, Joseph R Berger
exaly   +3 more sources

Progressive Multifocal Leukoencephalopathy

Neurologic Clinics, 1984
PML is a progressive opportunistic infection of the CNS caused by a commonly occurring virus that may become manifest in the context of reduced host resistance in persons of any age. The authors review the disease and its causes, including a discussion of treatment attempts and differential diagnoses.
B R, Brooks, D L, Walker
openaire   +2 more sources

Progressive Multifocal Leukoencephalopathy

Archives of Internal Medicine, 1963
Progressive multifocal leukoencephalopathy (PML) is a subacute demyelinating disease apparently resulting from the selective destruction of oligodendrocytes by papovaviruses. The pathology and pathogenesis of PML are distinct from those of the other slow infections of the human nervous system.
R F, JOHNSTON, R A, GREEN, J T, HEADINGTON   +2 more
openaire   +2 more sources

Progressive Multifocal Leukoencephalopathy

Radiology, 1976
The radionuclide, radiographic and pathologic findings in a patient with progressive multifocal leukoencephalopathy were correlated. Radionuclide imaging demonstrated the largest two of the many lesions observed at pathology. On repeated studies, one of the lesions developed a "doughnut" sign due to central necrosis. Cerebral angiography disclosed only
J, Kirsh, L, Rosenthall, M H, Finlayson, R, Wee   +3 more
openaire   +2 more sources

Progressive multifocal leukoencephalopathy

Current Infectious Disease Reports, 2001
Progressive multifocal leukoencephalopathy is a subacute demyelinating disease that occurs in patients with defects in cell-mediated immunity, including those with AIDS and lymphoproliferative disorders. It is caused by reactivation of JC virus (JCV), which infects 70% to 90% of the population by adulthood, but remains latent in normal hosts.
Anna R., Thorner, Joel T., Katz
openaire   +2 more sources

Progressive Multifocal Leukoencephalopathy

Archives of Ophthalmology, 1959
Astrom, Mancall, and Richardson1have recently directed attention to progressive multifocal leukoencephalopathy, a previously unrecognized neuropathological entity. Visual symptoms have been prominent in this disorder. As no cases have been reported in the ophthalmologic literature, the following instance of progressive multifocal leukoencephalopathy ...
openaire   +2 more sources

Progressive multifocal leukoencephalopathy

Journal of Neuroimmunology, 2011
Progressive multifocal leukoencephalopathy (PML) is a disease of the central nervous system (CNS) with destructive infection of oligodendrocytes by JC virus. PML belongs to the opportunistic infections. It is observed in patients with HIV infection, lymphoid malignancies, after organ- and stem cell transplantations and more recently in the context of ...
openaire   +3 more sources

Update on Progressive Multifocal Leukoencephalopathy

Current Neurology and Neuroscience Reports, 2012
Progressive multifocal leukoencephalopathy (PML) is a severe, often fatal, opportunistic viral infection of the central nervous system that is mainly seen in the context of AIDS and certain monoclonal immune-suppressive therapies. The causative agent, a polyoma virus, named JC virus infects only humans and there is no animal model for PML.
Israel, Steiner, Joseph R, Berger
openaire   +2 more sources

Viruses and Progressive Multifocal Leukoencephalopathy

New England Journal of Medicine, 1972
There has recently been an increasing interest in the relation between viruses and chronic degenerative diseases of the brain. Within the past few years, measles virus has been found to be associated with subacute sclerosing panencephalitis and transmissible agents have been isolated from patients with Kuru and Creutzfeldt—Jakob disease (spongiform ...
P H, Black, M S, Hirsch
openaire   +2 more sources

Progressive multifocal leukoencephalopathy and natalizumab

Journal of Neurology, 2011
Natalizumab (TYSABRI(®)), a specific α4-integrin antagonist, is approved as a second-line treatment of relapsing-remitting MS (RRMS) patients who fail therapy with interferons or as first-line treatment of patients with highly active relapsing-remitting disease. Since the market introduction of natalizumab as a monotherapy in July of 2006, 111 cases of
Kerstin, Hellwig, Ralf, Gold
openaire   +2 more sources